Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 5160-5165, October 1, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, K. J.
Right arrow Articles by Kaddurah-Daouk, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, K. J.
Right arrow Articles by Kaddurah-Daouk, R.

Cell Cycle Studies of Cyclocreatine, a New Anticancer Agent

Katherine J. Martin1, Elizabeth R. Winslow and Rima Kaddurah-Daouk

Amira, Inc., Cambridge, Massachusetts 02139

Cyclocreatine (CCr), a substrate analogue of creatine kinase (CK), exhibits antitumor activity in vitro and in vivo. To address its mechanism of action, we have examined its effects on tumor cell proliferation, viability, and cell cycle progression. Complete inhibition of proliferation of ME-180 cervical carcinoma cells was observed within 8 h of exposure to CCr and was characterized by an inhibition of progression out of all phases of the cell cycle. This initial effect was partially reversible on drug removal. Increased cytotoxicity was observed after several days of drug exposure and was most specific to cells in S. Previous studies have shown that CCr supports ATP regeneration through the CK system less efficiently than the natural substrate creatine and that CCr is active against tumor cell lines with elevated levels of CK. We propose here that the general inhibition of cell cycle progression reflects an effect of CCr on tumor cell energy availability through CK and that impaired energy homeostasis for several days leads to tumor cell death. Our results point out the unique nature of CCr as an anticancer agent that inhibits progression out of all phases of the cell cycle.

1 To whom requests for reprints should be addressed, at Amira, Inc., One Kendall Square, Building 700, Cambridge, MA 02139.

Received 5/12/94. Accepted 8/ 1/94.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Walzel, O. Speer, E. Boehm, S. Kristiansen, S. Chan, K. Clarke, J. P. Magyar, E. A. Richter, and T. Wallimann
New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle
Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E390 - E401.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Wyss and R. Kaddurah-Daouk
Creatine and Creatinine Metabolism
Physiol Rev, July 1, 2000; 80(3): 1107 - 1213.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.